Antibody-Drug Conjugates (ADCs) are “guided missiles” that deliver highly potent drugs directly to tumor cells. However, 90% of drug candidates fail because current preclinical models poorly reproduce human biology.

Syntopia combines scalable human 3D biology, microfluidics and AI-models to predict how these complex therapies behave in human tissues before clinical trials.

Human 3D biology
Perfused human 3D cultures reproducing key features of tumor biology, including spatial organization, long-term viability and treatment response.

Scalable data generation
Microfluidic technology compatible with standard laboratory workflows and automation, enabling the high-throughput generation of spatial and temporal read-outs.

AI-models for biological insights
Predictive AI models of drug effect at the tissue level for therapeutic efficacy, mechanism of action and candidate prioritization.

Syntopia accelerates the development of safer and more effective ADC therapies for patients by delivering predictive biological insights to pharmaceutical companies.